MDGL Reinstated by Goldman Sachs -- Price Target Announced at $704

gurufocus.com · 2026-09-24

On October 03, 2023, Goldman Sachs reinstated Madrigal Pharmaceuticals (MDGL) with a "Buy" rating. The new price target is set at $704.00. Current ma